Trial Profile
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster; Postherpetic neuralgia; Varicella zoster virus infections
- Focus Registrational; Therapeutic Use
- Acronyms ZOE-70
- Sponsors GlaxoSmithKline; GSK
- 25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.
- 23 Mar 2018 According to a GlaxoSmithKline media release, European Commission and the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN), the most common and often painful shingles-related complication, in adults aged 50 years or older.
- 26 Feb 2018 Results of pooled data from two trials (NCT01165177 and NCT01165229), were published in the Journal of Infectious Diseases.